Immune response to SARS-CoV-2 mRNA vaccination in multiple sclerosis patients after rituximab treatment interruption

Peripheral B cell depletion via anti-CD20 treatment is a highly effective disease-modifying treatment for reducing new relapses in multiple sclerosis (MS) patients. A drawback of rituximab (RTX) and other anti-CD20 antibodies is a poor immune response to vaccination. While this can be mitigated by t...

Descripción completa

Detalles Bibliográficos
Autores principales: Gröning, Remigius, Dernstedt, Andy, Ahlm, Clas, Normark, Johan, Sundström, Peter, Forsell, Mattias N. E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10413123/
https://www.ncbi.nlm.nih.gov/pubmed/37575257
http://dx.doi.org/10.3389/fimmu.2023.1219560

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10413123/
https://www.ncbi.nlm.nih.gov/pubmed/37575257
http://dx.doi.org/10.3389/fimmu.2023.1219560

Ejemplares similares